MMWR Vol. 65 / No. SS-7 ► Neisseria gonorrhoeae Antimicrobial Susceptibility Surveillance — The Gonococcal Isolate Surveillance Project, 27 Sites, United States, 2014 | MMWR

MMWR Surveillance Summaries Vol. 65, No. SS-7 July 15, 2016

PDF

Neisseria gonorrhoeae Antimicrobial Susceptibility Surveillance — The Gonococcal Isolate Surveillance Project, 27 Sites, United States, 2014 
Robert D. Kirkcaldy, MD; Alesia Harvey; John R. Papp, PhD; et al.
MMWR Surveill Summ 2016;65:1–19

Gonorrhea is the second most commonly reported notifiable disease in the United States. Prevention of sequelae and of transmission to sexual partners relies on prompt detection and effective treatment. However, treatment has been compromised by the absence of routine antimicrobial susceptibility testing in clinical care and evolution of antimicrobial resistance to the antibiotics used to treat gonorrhea. Dual therapy with ceftriaxone plus azithromycin is the only recommended gonorrhea treatment, and the potential threat of cephalosporin-resistant gonorrhea is a cause for concern. This report presents comprehensive surveillance data from the Gonococcal Isolate Surveillance Project and describes gonococcal antimicrobial susceptibility patterns in the United States during 2000–2014. Antimicrobial susceptibility surveillance data can be used to develop national treatment recommendations, set research and prevention priorities, and communicate best treatment practices to health care providers.

Neisseria gonorrhoeae Antimicrobial Susceptibility Surveillance — The Gonococcal Isolate Surveillance Project, 27 Sites, United States, 2014 | MMWR